BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 17449961)

  • 21. [Cystic pancreatic tumors: diagnostics and new biomarkers].
    Berger AW; Seufferlein T; Kleger A
    Chirurg; 2017 Nov; 88(11):905-912. PubMed ID: 28831506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification.
    Serikawa M; Sasaki T; Fujimoto Y; Kuwahara K; Chayama K
    J Clin Gastroenterol; 2006 Oct; 40(9):856-62. PubMed ID: 17016145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic alterations in precancerous pancreatic lesions and their clinical implications.
    Turrini O; Cano C; Legoffic A; Delpero JR; Dagorn JC; Iovanna J
    Gastroenterol Clin Biol; 2009; 33(10-11):1028-35, e1-9. PubMed ID: 19766418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Where and when does pancreatic carcinoma start?
    Lüttges J; Hahn S; Klöppel G
    Med Klin (Munich); 2004 Apr; 99(4):191-5. PubMed ID: 15085289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
    Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
    Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms.
    Nara S; Shimada K; Kosuge T; Kanai Y; Hiraoka N
    Am J Surg Pathol; 2008 Feb; 32(2):243-55. PubMed ID: 18223327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic intraepithelial neoplasia revisited and updated.
    Sipos B; Frank S; Gress T; Hahn S; Klöppel G
    Pancreatology; 2009; 9(1-2):45-54. PubMed ID: 19077454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathologic characteristics and evaluation of the pancreatic cancer].
    Fukushima N; Mukai K
    Gan To Kagaku Ryoho; 2005 May; 32(5):599-604. PubMed ID: 15918557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pathology of intraductal papillary-mucinous tumor of the pancreas].
    Nobukawa B; Suda K; Yamasaki S; Takase M; Fukumura Y; Shiono S
    Nihon Geka Gakkai Zasshi; 2003 Jun; 104(6):439-42. PubMed ID: 12854489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Premalignant cystic neoplasms of the pancreas.
    Dudeja V; Allen PJ
    Semin Oncol; 2015 Feb; 42(1):70-85. PubMed ID: 25726053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
    Hiraoka N; Onozato K; Kosuge T; Hirohashi S
    Clin Cancer Res; 2006 Sep; 12(18):5423-34. PubMed ID: 17000676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?
    Chidambaram S; Kawka M; Gall TM; Cunningham D; Jiao LR
    Future Oncol; 2022 Jul; 18(23):2605-2612. PubMed ID: 35730473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Strategies for screening for pancreatic adenocarcinoma in high-risk patients].
    Béchade D
    Bull Cancer; 2011 Jul; 98(7):827-36. PubMed ID: 21684836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classification, Morphology, Molecular Pathogenesis, and Outcome of Premalignant Lesions of the Pancreas.
    Pittman ME; Rao R; Hruban RH
    Arch Pathol Lab Med; 2017 Dec; 141(12):1606-1614. PubMed ID: 29189063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on the pathology and genetics of exocrine pancreatic tumors with ductal phenotype: precursor lesions and new tumor entities.
    Lüttges J; Klöppel G
    Dig Dis; 2001; 19(1):15-23. PubMed ID: 11385247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive genomic alterations in intraductal papillary mucinous tumours of the pancreas and morphologically similar lesions of the pancreatic ducts.
    Soldini D; Gugger M; Burckhardt E; Kappeler A; Laissue JA; Mazzucchelli L
    J Pathol; 2003 Apr; 199(4):453-61. PubMed ID: 12635136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas.
    Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N
    Ann Surg Oncol; 2007 Nov; 14(11):3174-80. PubMed ID: 17694416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas.
    Ikenaga N; Ohuchida K; Mizumoto K; Yu J; Kayashima T; Hayashi A; Nakata K; Tanaka M
    Hum Pathol; 2010 Oct; 41(10):1466-74. PubMed ID: 20619441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histologic characteristics of pancreatic intraepithelial neoplasia associated with different pancreatic lesions.
    Recavarren C; Labow DM; Liang J; Zhang L; Wong M; Zhu H; Wang J; Francis F; Xu R
    Hum Pathol; 2011 Jan; 42(1):18-24. PubMed ID: 21056895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Familial Pancreatic Cancer.
    Benzel J; Fendrich V
    Oncol Res Treat; 2018; 41(10):611-618. PubMed ID: 30269130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.